Protagonist Therapeutics Inc (PTGX) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Protagonist Therapeutics inc   (NASDAQ: PTGX)


Protagonist Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Protagonist Therapeutics Inc's ROI in the second quarter of 2026?
Protagonist Therapeutics inc achieved a return on average invested assets (ROI) of 11.66 % in its second quarter of 2026, this is above PTGX's average return on investment of -30.51%.
Protagonist Therapeutics Inc invested over the 12 months ending in its second quarter of 2026 $698 million

ROI has improved compared to -17.61% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 90 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3250 to 3279.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 4.8 % 4.14 % 11.03 % 34.11 % 47.84 %
Y / Y Net Income Change TTM 56.32 % - - - -
Investment (TTM) in Millions 848 663 623 657 699
Return On Investment (TTM) 11.66 % -17.61 % -19.62 % 6.65 % 7.82 %
PTGX's Overall Ranking # 3279 # 3250 # 1174 # 901 #
Seq. Investment Change TTM 5.64 % -1.64 % -2.7 % 3.66 % 4.98 %
Seq. Net Income Change TTM - - - -11.78 % -7.39 %
Net Income (TTM) in Millions 81 -116 -132 46 52

PTGX Company Profile >> Back to PTGX Roi Comparisons >> See Annual PTGX Return On Investment



Return On Investment PTGX's Ranking
Within: No.
Industry # 38
Sector # 91
Overall # 3279

Return On Investment Statistics
High Average Low
45.5 %
-30.51 %
-72.84 %
(Dec 31 2024)   (Mar 31 2020)







Financial Statements
Protagonist Therapeutics Inc's II. Quarter Investments $ 848 Millions PTGX's Balance sheet
Protagonist Therapeutics Inc's II. Quarter Income $ 163 Millions Quarterly PTGX's Income Statement
PTGX's Income by Division See PTGX's Income by Division


PTGX Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 623 697 337 217 304
Y / Y Investment Growth -10.7 % 107.12 % 55.33 % -28.63 % 6.84 %
Net Income in Millions -130 275 -79 -127 -126
Y / Y Net Income Growth - - - - -
Annual Return On Investment -20.9 % 39.46 % -23.45 % -58.77 % -41.34 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
PTGX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for PTGX's Competitors
Subscribers only: Roi for Protagonist Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for PTGX's Customers

Other Ratios
PTGX's Roa PTGX's Inventory Turnover Ratio PTGX's Growth Rates PTGX's Dividend Statistics
PTGX's Profitability Ratios PTGX's Asset Turnover Ratio PTGX's Dividend Growth
PTGX's Roe PTGX's Valuation Ratios PTGX's Financial Strength Ratios PTGX's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %
Agilent Technologies inc   19.84 %
Illumina Inc   19.61 %
Puma Biotechnology Inc   19.60 %
United Therapeutics Corporation  19.53 %
Zoetis Inc   19.44 %
Krystal Biotech Inc   19.16 %
Carlisle Companies Incorporated  18.88 %
Neurocrine Biosciences Inc   17.51 %
Intuitive Surgical Inc   17.11 %
Theravance Biopharma inc   17.10 %
Standard Biotools Inc   16.38 %
Inspire Medical Systems inc   16.34 %

Date modified: 2026-09-11T09:50:26+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.